We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causin... Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients. Show more
WATERTOWN, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using...
BP plc (NYSE:BP) – BP expects weak margins in its refining business to impact its second-quarter profits by up to $700 million. The decline in refining margins, due to excess renewable...
WATERTOWN, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using...
KT-333 demonstrated initial clinical proof of concept across multiple hematological malignancies, including complete responses in two patients with Hodgkin’s lymphoma Robust STAT3 knockdown and...
KT-253 demonstrates initial clinical proof of concept in patients with tumor types shown to be sensitive in preclinical models, including responses in MCC and AML Evidence of target engagement and...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.7 | 1.65094339623 | 42.4 | 48.7 | 41.8428 | 820176 | 46.10213794 | CS |
| 4 | 10.79 | 33.3952336738 | 32.31 | 48.7 | 29.24 | 822749 | 37.91485822 | CS |
| 12 | 9.35 | 27.7037037037 | 33.75 | 48.7 | 29.24 | 619712 | 35.95312182 | CS |
| 26 | 15.23 | 54.6465733764 | 27.87 | 48.7 | 27.17 | 638125 | 36.76691557 | CS |
| 52 | 21.51 | 99.6294580824 | 21.59 | 48.7 | 9.6 | 679924 | 27.87241196 | CS |
| 156 | -13.94 | -24.4389901823 | 57.04 | 69.12 | 9.6 | 585788 | 30.60733118 | CS |
| 260 | 10.18 | 30.9234507898 | 32.92 | 91.92 | 9.6 | 520746 | 33.10117564 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
